Clinical Trials Browser

OTHER × Interventional × Erlotinib Hydrochloride × Clear all

NCT06997068 2026-04-17

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

Mouth Neoplasms

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2 Active not recruiting

50 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT03403049 2026-04-13

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT00602667 2026-01-13

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Phase 2 Active not recruiting

293 enrolled 89 charts

Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor

NCT01927744 2025-11-26

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Phase 2 Completed

55 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT04172779 2025-11-20

ECHO-B

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT00977470 2025-10-15

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Phase 2 Active not recruiting

76 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00885066 2025-09-30

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00954226 2025-09-05

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Phase 1 Completed

Salivary Gland Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1 Completed

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT00954525 2025-05-02

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Phase 2 Completed

17 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT00448240 2025-03-18

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Phase 2/3 Terminated

6 enrolled 4 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00503971 2025-03-07

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Phase 1/2 Terminated

33 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT00720304 2024-08-22

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

43 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01064479 2024-07-16

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

123 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT00254384 2024-07-05

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1/2 Completed

24 enrolled 8 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01116622 2023-10-18

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Phase 1 Completed

GastrointestinalHead & Neck

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

NCT01174043 2023-10-13

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Phase 2 Completed

11 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Myelomonocytic, Acute

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05904457 2023-06-15

BRISK

Phase 2 Unknown

Neoplasm Metastasis, Neoplasms

NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00597597 2023-05-17

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Phase 2 Terminated

11 enrolled 12 charts

Breast Neoplasms

NCT02942095 2023-04-18

Study of Ixazomib and Erlotinib in Solid Tumors

Phase 1 Completed

Neoplasm Metastasis

NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT01515137 2023-03-28

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02633189 2023-03-24

BEVERLY

Phase 3 Unknown

Non-squamous Non-small Cell Lung Cancer

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01180959 2022-11-07

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Phase 2 Completed

45 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00553800 2022-07-12

NSCLC

Phase 2 Completed

32 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT03086538 2022-06-15

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms

NCT03110484 2022-06-15

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT00883480 2022-06-13

SLAT

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT00600015 2022-03-10

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

166 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT00393068 2022-03-02

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2 Completed

62 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms